glycine has been researched along with Leukocytopenia in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report the first clinical investigation conducted in Japan to confirm the safety, tolerability, and pharmacokinetics of ixazomib alone and combined with lenalidomide-dexamethasone (Rd) in Japanese patients with relapsed/refractory multiple myeloma." | 9.24 | Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. ( Chou, T; Handa, H; Ishizawa, K; Kase, Y; Suzuki, K; Takubo, T, 2017) |
| "Objective To evaluate the safety profile of ixazomib combined with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) in clinical practice in Japan through an all-case post-marketing surveillance." | 8.12 | Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance. ( Chou, T; Hashimoto, M; Hiraizumi, M; Hoshino, M; Kakimoto, Y; Shimizu, K, 2022) |
| "We report the first clinical investigation conducted in Japan to confirm the safety, tolerability, and pharmacokinetics of ixazomib alone and combined with lenalidomide-dexamethasone (Rd) in Japanese patients with relapsed/refractory multiple myeloma." | 5.24 | Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. ( Chou, T; Handa, H; Ishizawa, K; Kase, Y; Suzuki, K; Takubo, T, 2017) |
| "Objective To evaluate the safety profile of ixazomib combined with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) in clinical practice in Japan through an all-case post-marketing surveillance." | 4.12 | Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance. ( Chou, T; Hashimoto, M; Hiraizumi, M; Hoshino, M; Kakimoto, Y; Shimizu, K, 2022) |
| " LPS-induced pulmonary vascular injury was significantly attenuated in rats with methotrexate-induced leukocytopenia or treated with ONO-5046, a potent granulocyte elastase inhibitor, although ONO-5046 did not inhibit the LPS-induced increase in serum FDP (E)." | 3.69 | Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats. ( Murakami, K; Okabe, H; Okajima, K; Takatsuki, K; Uchiba, M, 1995) |
| "The rate of endogenous carbon monoxide production ( Vco), determined by the closed rebreathing system technique, was elevated above the normal range in four of five patients studied with ineffective erythropoiesis (four patients with primary refractory anemia, one with thalassemia)." | 3.64 | Carbon monoxide production associated with ineffective erythropoiesis. ( Coburn, RF; Goldwein, MI; Rother, ML; Shafer, BC; White, P; Williams, WJ, 1967) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (42.86) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kakimoto, Y | 1 |
| Hoshino, M | 1 |
| Hashimoto, M | 1 |
| Hiraizumi, M | 1 |
| Shimizu, K | 1 |
| Chou, T | 2 |
| Montesinos, P | 1 |
| Recher, C | 1 |
| Vives, S | 1 |
| Zarzycka, E | 1 |
| Wang, J | 1 |
| Bertani, G | 1 |
| Heuser, M | 1 |
| Calado, RT | 1 |
| Schuh, AC | 1 |
| Yeh, SP | 1 |
| Daigle, SR | 1 |
| Hui, J | 1 |
| Pandya, SS | 1 |
| Gianolio, DA | 1 |
| de Botton, S | 1 |
| Döhner, H | 1 |
| Suzuki, K | 1 |
| Handa, H | 1 |
| Ishizawa, K | 1 |
| Takubo, T | 1 |
| Kase, Y | 1 |
| ISHII, Y | 1 |
| TAKEISHI, T | 1 |
| IWATA, H | 1 |
| NAKAJIMA, K | 1 |
| SANTO, H | 1 |
| Soriano, JR | 1 |
| Taitz, LS | 1 |
| Finberg, L | 1 |
| Edelmann, CM | 1 |
| White, P | 1 |
| Coburn, RF | 1 |
| Williams, WJ | 1 |
| Goldwein, MI | 1 |
| Rother, ML | 1 |
| Shafer, BC | 1 |
| Gerbasi, F | 1 |
| Scotto, E | 1 |
| Gueci, G | 1 |
| Uchiba, M | 3 |
| Okajima, K | 4 |
| Murakami, K | 4 |
| Okabe, H | 3 |
| Takatsuki, K | 3 |
| Matsukawa, A | 1 |
| Ohkawara, S | 1 |
| Maeda, T | 1 |
| Takagi, K | 1 |
| Yoshinaga, M | 1 |
| Johno, M | 1 |
| Nakagaki, T | 1 |
| Harada, N | 2 |
| Tanaka, K | 1 |
| Liu, W | 1 |
| Isobe, H | 1 |
| Irie, T | 1 |
| Broyer, M | 1 |
| Berger, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation[NCT03173248] | Phase 3 | 146 participants (Actual) | Interventional | 2017-06-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
EFS was defined as the time from randomization until treatment failure, relapse from remission, or death from any cause, whichever occurs first. Treatment failure was defined as failure to achieve complete remission (CR) by Week 24. CR: Bone marrow blasts <5% and no Auer rods; absence of extramedullary disease; Absolute neutrophil count (ANC) ≥1.0 × 10^9 per litre (10^9/L) (1000 per microlitre [1000/μL]); platelet count ≥100 × 10^9/L (100,000/μL); independence of red blood cell transfusions. Participants who had an EFS event (relapse or death) after, 2 or more missing disease assessments were censored at the last adequate disease assessment documenting no relapse before the missing assessments. The reported data represents the Kaplan-Meier median value. (NCT03173248)
Timeframe: Up to Week 24
| Intervention | months (Median) |
|---|---|
| AG-120 + Azacitidine | 0.03 |
| Placebo + Azacitidine | 0.03 |
2 trials available for glycine and Leukocytopenia
| Article | Year |
|---|---|
Ivosidenib and Azacitidine in
Topics: Antineoplastic Agents; Azacitidine; Febrile Neutropenia; Glycine; Humans; Isocitrate Dehydrogenase; | 2022 |
Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boron Compounds; Dexamethasone; | 2017 |
12 other studies available for glycine and Leukocytopenia
| Article | Year |
|---|---|
Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dex | 2022 |
[Side-effects of antineoplastic agents and their treatment].
Topics: Adrenochrome; Antineoplastic Agents; Cysteine; Glycine; Humans; Leukopenia; Vitamin A; Vitamin K; Vi | 1963 |
[THE EFFECT OF ALPHA-THIOLA (ALPHA-MERCAPTO-PROPIONYL-GLYCINE) ON THE LEUKOPENIA INDUCED BY THE TREATMENT WITH SOME ANTICANCER AGENTS].
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Glycine; Leukopenia; Mice; Pharmacology; P | 1964 |
Hyperglycinemia with ketoacidosis and leukopenia. Metabolic studies on the nature of the defect.
Topics: Acidosis; Amino Acid Metabolism, Inborn Errors; Amino Acids; Ammonia; Diet Therapy; Dietary Proteins | 1967 |
Carbon monoxide production associated with ineffective erythropoiesis.
Topics: Adolescent; Adult; Aged; Anemia; Anemia, Sideroblastic; Bile Pigments; Bilirubin; Carbon Isotopes; C | 1967 |
[Ketotic hyperglycinemic syndrome].
Topics: Agammaglobulinemia; Amino Acid Metabolism, Inborn Errors; Female; Glycine; Humans; Infant; Ketosis; | 1982 |
Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats.
Topics: Amino Acid Chloromethyl Ketones; Amino Acid Sequence; Animals; Anticoagulants; Antithrombin III; Cap | 1995 |
Production of IL-1 and IL-1 receptor antagonist and the pathological significance in lipopolysaccharide-induced arthritis in rabbits.
Topics: Animals; Arthritis; Female; Glycine; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Leuko | 1993 |
Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.
Topics: Amino Acid Chloromethyl Ketones; Amino Acid Sequence; Animals; Anticoagulants; Antithrombin III; Cap | 1996 |
Leukocyte depletion and ONO-5046, a specific inhibitor of granulocyte elastase, prevent a stress-induced decrease in gastric prostaglandin I2 in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Epoprostenol; Gastric Mucosa; Glycine; Iloprost; Leukocyte El | 1997 |
Role of neutrophil elastase in stress-induced gastric mucosal injury in rats.
Topics: Animals; Capillary Permeability; Cephalosporins; Disease Models, Animal; Gastric Mucosa; Glycine; Le | 1998 |
[Glycinosis (hyperglycinemia)].
Topics: Acidosis; Amino Acid Metabolism, Inborn Errors; Amino Acids; Child Development; Child, Preschool; Ch | 1968 |